Gene · 23091
Papers1,599
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 1,599
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| N(6)-methyladenosine modification of ADGRA3 by ZC3H13 suppresses papillary thyroid cancer cell malignancy by inactivating the PI3K/Akt/mTOR signaling pathway. | Discov Oncol | 2025 | 40890321 | PubTator, text mining | PubMed |
| Identification and experimental validation of biomarkers related to mitochondrial and programmed cell death in obsessive-compulsive disorder. | Sci Rep | 2025 | 40885831 | PubTator, text mining | PubMed |
| Comprehensive Transcriptomic and m6A Epitranscriptomic Analysis Reveals Colchicine-Induced Kidney Toxicity via DNA Damage and Autophagy in HK2 Cells. | Toxins (Basel) | 2025 | 40864084 | PubTator, text mining | PubMed |
| Emerging implications of N6-methyladenosine in prostate cancer progression and treatment. | Cell Death Discov | 2025 | 40830264 | PubTator, text mining | PubMed |
| Comprehensive bioinformatics analysis of EXOSC family genes in head and neck squamous cell carcinoma. | Sci Rep | 2025 | 40830179 | PubTator, text mining | PubMed |
| Epigenetic control in thyroid cancer: mechanisms and clinical perspective. | Cell Death Discov | 2025 | 40819127 | PubTator, text mining | PubMed |
| ZC3H13 facilitates the progression of acute myeloid leukemia through m6A-FOXP1-mediated metabolic reprogramming. | Exp Hematol | 2025 | 40780498 | PubTator, text mining | PubMed |
| ZC3H13 mediates N6-methyladenosine modification of SNTB1 to promote epithelial-mesenchymal transition in gastric cancer. | Cell Death Dis | 2025 | 40774945 | PubTator, text mining | PubMed |
| The role of epigenetics in pulmonary fibrosis: recent advances in mechanistic insights and therapeutic implications. | Front Mol Biosci | 2025 | 40746422 | PubTator, text mining | PubMed |
| M6A RNA modification: focusing on non-small cell lung cancer progression, therapeutic strategies and challenges. | Front Oncol | 2025 | 40740874 | PubTator, text mining | PubMed |
| RNA m6A modification: a key regulator in normal and malignant processes. | Cell Investig | 2025 | 40734692 | PubTator, text mining | PubMed |
| A Bioinformatics Analysis on the Subtypes of Hepatocellular Carcinoma Related to RNA Processing Genes to Reveal Prognosis and Immune Microenvironment Features. | Dig Dis Sci | 2025 | 40719833 | PubTator, text mining | PubMed |
| M6A methyltransferase ZC3H13-mediated downregulation of GPX4 mRNA stability inhibits the progression of kidney renal clear cell carcinoma (KIRC). | Cell Immunol | 2025 | 40578066 | PubTator, text mining | PubMed |
| The Multifaceted Roles of Zinc Finger Proteins in Pluripotency and Reprogramming. | Int J Mol Sci | 2025 | 40507915 | PubTator, text mining | PubMed |
| Integration of Bulk and Single-Cell RNA Sequencing to Identify RNA Modifications-Related Prognostic Signature in Ovarian Cancer. | Int J Gen Med | 2025 | 40417417 | PubTator, text mining | PubMed |
| LMO2 confers value as a potential immunotherapy marker in pan-cancer analysis and inhibits progression of Clear Cell Renal Cell Carcinoma. | Transl Oncol | 2025 | 40344914 | PubTator, text mining | PubMed |
| Exploration of mRNA-modifying METTL3 oncogene as momentous prognostic biomarker responsible for colorectal cancer development. | Open Med (Wars) | 2025 | 40177651 | PubTator, text mining | PubMed |
| The inhibition of ZC3H13 attenuates G2/M arrest and apoptosis by alleviating NABP1 m6A modification in cisplatin-induced acute kidney injury. | Cell Mol Life Sci | 2025 | 39985591 | PubTator, text mining | PubMed |
| Identification of m6A methyltransferase-related WTAP and ZC3H13 predicts immune infiltrates in glioblastoma. | Sci Rep | 2025 | 39910141 | PubTator, text mining | PubMed |
| ZC3H13 may participate in the ferroptosis process of sepsis-induced cardiomyopathy by regulating the expression of Pnn and Rbm25. | Gene | 2025 | 39284557 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/23091/papers?page=3